These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32562244)

  • 1. Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.
    Men P; Qu S; Song Z; Liu Y; Li C; Zhai S
    Diabetes Ther; 2020 Aug; 11(8):1745-1755. PubMed ID: 32562244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.
    Men P; Qu S; Luo W; Li C; Zhai S
    Diabetes Obes Metab; 2020 Jan; 22(1):107-115. PubMed ID: 31469217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.
    Shu H; Gu LN; Men LC; Lu JM
    Diabetes Ther; 2016 Dec; 7(4):777-792. PubMed ID: 27796905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
    Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
    J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.
    Scott LJ
    BioDrugs; 2013 Oct; 27(5):509-23. PubMed ID: 23918699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
    Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
    PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
    Eto K; Naito Y; Seino Y
    Diabetol Metab Syndr; 2015; 7():106. PubMed ID: 26594250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Wei ZG; Wang MC; Zhang HH; Wang ZY; Wang GN; Wei FX; Zhang YW; Xu XD; Zhang YC
    Medicine (Baltimore); 2018 Dec; 97(51):e13710. PubMed ID: 30572502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
    Trujillo JM; Goldman J
    Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Hong T; Lu J; Zhang P; Zhang Z; Xu Q; Li Y; Cui N; Grijalva A; Murray EM; Del Aguila MA; Bi Y
    Diabetes Ther; 2019 Jun; 10(3):1051-1066. PubMed ID: 30955140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
    Raccah D
    Expert Rev Endocrinol Metab; 2013 Mar; 8(2):105-121. PubMed ID: 30736171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis.
    Gao Y; Wang K; Chen Y; Shen L; Hou J; Xuan J; Liu B
    Diabetes Ther; 2018 Apr; 9(2):673-682. PubMed ID: 29476413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.
    Hassanein MM; Sahay R; Hafidh K; Djaballah K; Li H; Azar S; Shehadeh N; Hanif W
    Diabetes Res Clin Pract; 2019 Apr; 150():331-341. PubMed ID: 30772385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.